We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

JRVR:NASDAQJames River Group Holdings, Inc. Analysis

Data as of 2026-06-11 - not real-time

$4.18

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

James River Group Holdings trades at $4.18, just above the calculated support of $3.80 and well below its 20‑day SMA of $4.03, indicating short‑term pressure despite a bullish MACD histogram and an RSI near the midpoint (42.8). Volatility is extreme at 90% over the past 30 days, while beta is unusually low (≈0.2), suggesting price swings are driven more by company‑specific factors than market moves. The bearish trend direction and decreasing volume reinforce a cautious near‑term outlook, but the technical picture shows a slight bullish tilt as the MACD line sits above its signal.
Fundamentally, JRVR reports a 12% revenue decline, thin operating margins (‑3.3%) and modest profit margin (4.3%), yet its forward EPS is projected to rise to $1.11, compressing the forward P/E to 3.8×. The stock trades at a PE of 9.9× versus an industry average of 16.5×, a price‑to‑book of 0.36× and a price‑to‑sales of 0.29×, all pointing to deep undervaluation. Free cash flow of $215.6 M dwarfs the $0.04 dividend, yielding a sustainable 0.96% payout. A DCF model implies a fair value near $58.8, translating to a ~28% upside over current levels, while activist investor activity and a recent UBS downgrade to neutral add both catalyst potential and short‑term uncertainty.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support with bearish trend
  • Decreasing volume and high short‑term volatility
  • Potential catalyst from activist stakeholder but limited upside

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Significant valuation gap (price vs DCF and peers)
  • Improving forward earnings and low payout ratio
  • Analyst price targets suggesting 75% upside

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Deep undervaluation with strong free cash flow generation
  • Low beta and defensive dividend profile
  • Long‑term upside potential from DCF and sector consolidation

Key Metrics & Analysis

Financial Health

Revenue Growth-12.10%
Profit Margin4.34%
P/E Ratio10.0
ROE4.74%
ROA0.61%
Debt/Equity50.63
P/B Ratio0.4
Op. Cash Flow$32.0M
Free Cash Flow$215.6M
Industry P/E16.5

Technical Analysis

TrendBearish
RSI42.8
Support$3.80
Resistance$4.42
MA 20$4.03
MA 50$5.15
MA 200$5.81
MACDBullish
VolumeDecreasing
Fear & Greed Index83.29

Valuation

Fair Value$58.82
Target Price$5.38
Upside/Downside28.59%
GradeUndervalued
TypeValue
Dividend Yield0.96%

Risk Assessment

Beta0.21
Volatility90.25%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.